Oric Pharmaceuticals CFO exercises and sells 600 shares

The reported sales were made under a Rule 10b5-1 trading plan adopted on May 26, 2026.

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 600 options on September 24, 2026, at an exercise price of $4.3600 per share, acquiring 600 common shares. On the same date, he sold 100 shares at $13.5000 per share and 500 shares at $13.5050 per share. The sales were made under a Rule 10b5-1 trading plan adopted on May 26, 2026. The option row reports 91,900 shares following the transaction.

Insider Trade Summary 10b5-1

Exercise and Sale: 600 shares ($5K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Piscitelli Dominic

Role Chief Financial Officer

Sold 600 shs ($8K)

Approx. gross sale proceeds $8K

Approx. exercise cost $3K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	600	$0.00	$0.00
Exercise	Common Stock	600	$4.36	$3K
Sale	Common Stock F1	100	$13.50	$1K
Sale	Common Stock F1	500	$13.505	$7K

Holdings After Transaction: Stock Option (right to buy) — 91,900 contracts (Direct); Common Stock — 69,828 shares (Direct)

Footnotes (1)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

Key Figures

Options exercised: 600 options Option exercise price: $4.3600 per share Common shares acquired: 600 shares +3 more

6 metrics

Options exercised 600 options September 24, 2026

Option exercise price $4.3600 per share Exercise reported on September 24, 2026

Common shares acquired 600 shares September 24, 2026

First sale price $13.5000 per share 100 shares sold on September 24, 2026

Second sale price $13.5050 per share 500 shares sold on September 24, 2026

Shares following option transaction 91,900 shares Option row following the September 24, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), Exercise or conversion of derivative security

3 terms

Rule 10b5-1 trading plan financial

"sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

Exercise or conversion of derivative security financial

"Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORIC shares did Dominic Piscitelli sell, and at what prices?

Dominic Piscitelli sold 600 common shares on September 24, 2026: 100 at $13.5000 per share and 500 at $13.5050 per share. The sales were made under a Rule 10b5-1 trading plan adopted on May 26, 2026.

How many ORIC options did Dominic Piscitelli exercise?

Dominic Piscitelli exercised 600 options at an exercise price of $4.3600 per share, acquiring 600 common shares on September 24, 2026. The option row reports 91,900 shares following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 08:00 PM Accepted by SEC EDGAR 09/25/2026 - 07:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2026		M		600	A	$4.36	70,428	D
Common Stock	09/24/2026		S(1)		100	D	$13.5	70,328	D
Common Stock	09/24/2026		S(1)		500	D	$13.505	69,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	09/24/2026		M			600	07/20/2025	07/19/2032	Common Stock	600	$0	91,900	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

	/s/ Christian Kuhlen, attorney-in-fact	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)